Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Vaccine ; 34(45): 5414-5419, 2016 10 26.
Article in English | MEDLINE | ID: mdl-27498212

ABSTRACT

The Global Action Plan (GAP) for Influenza Vaccines is a decade-long initiative that brings together a diverse range of stakeholders to work towards reducing anticipated global shortage of influenza vaccines and ensuring more equitable access to vaccines during the next influenza pandemic. Since its inception in 2006, significant progress has been made towards all the main objectives of GAP, namely: (1) an increase in seasonal vaccine use, (2) an increase in vaccine production, and (3) progress in research and development of more effective vaccines. The Technology Transfer Initiative (TTI), conceived and managed by WHO under the GAP, contributed to increasing regional influenza vaccine production capacity. This was achieved by facilitating technology transfer in 14 low- and middle-income countries, through grants to manufacturers to establish or strengthen influenza vaccine production capacity and support to their national regulatory authorities. Five of the countries subsequently licensed locally produced influenza vaccines; two pandemic and three seasonal vaccines received WHO prequalification. The success of GAP can be largely attributed to the regulatory support provided by WHO to both manufacturers and regulators. This support had two components: (1) direct regulatory support to GAP/TTI, and (2) support to GAP-related WHO programmes, such as the Pandemic Influenza Vaccine Deployment Initiative in 2010 and the Pandemic Influenza Preparedness Framework since 2013, especially in non-vaccine-producing countries. Temporary adaptation of the assessment process for influenza vaccines in the WHO Vaccine Prequalification Programme to the A(H1N1) pandemic situation in 2009 was instrumental to the success of the WHO Pandemic Influenza Vaccine Deployment Initiative in its attempt to meet the demand for pandemic vaccines in countries that received donated vaccines.


Subject(s)
Disease Outbreaks/prevention & control , Drug Industry/standards , Influenza Vaccines/standards , Influenza, Human/prevention & control , World Health Organization , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza, Human/epidemiology , Licensure , Seasons , Technology Transfer , Time Factors
2.
Vaccine ; 33(47): 6493-8, 2015 Nov 25.
Article in English | MEDLINE | ID: mdl-26319745

ABSTRACT

There is potential for influenza vaccine programmes to make a substantial impact on severe disease in low-resource settings, however questions around vaccine composition and programmatic issues will require special attention. Some countries may benefit from immunization programmes that provide year-round supply of vaccine; however the best way to ensure adequate vaccine supply has yet to be determined. In this report, we discuss vaccine composition, availability, and programmatic issues that must be considered when developing year-round influenza immunization programmes. We then explore how these considerations have influenced immunization practices in the Latin American region as a case study. We identify three different approaches to achieve year-round supply: (1) alternating between Northern Hemisphere and Southern Hemisphere formulations, (2) extending the expiration date to permit extended use of a single hemisphere formulation, and (3) local vaccine manufacture with production timelines that align with local epidemiology. Each approach has its challenges and opportunities. The growing data suggesting high influenza disease burden in low resource countries underscores the compelling public health need to determine the best strategies for vaccine delivery.


Subject(s)
Immunization Programs/organization & administration , Influenza Vaccines/supply & distribution , Influenza, Human/prevention & control , Humans , Influenza, Human/epidemiology , Latin America/epidemiology
3.
Vaccine ; 29 Suppl 1: A2-7, 2011 Jul 01.
Article in English | MEDLINE | ID: mdl-21684422

ABSTRACT

Should a highly pathogenic avian influenza virus, such as the H5N1 virus type currently circulating in birds, become transmissible among humans, an effective vaccine, rapidly available in vast quantities, would be the best tool to prevent high case-fatalities and the breakdown of health and social services. The number of vaccine doses that could be produced on demand has risen sharply over the last few years; however, it is still alarmingly short of the 13 billion doses that would be needed if two doses were required to protect fully the world's population. Most developing countries would be last in the queue to benefit from a pandemic vaccine. The World Health Organization, together with governments, the pharmaceutical industry and other stakeholders, has been implementing the global pandemic influenza action plan to increase vaccine supply since 2006. Building capacity in developing countries to manufacture influenza vaccine is an integral part of this plan, as well as research and development into more efficacious technologies, e.g. those that allow significant dose-sparing. To this end, the influenza vaccine technology transfer initiative was launched in 2007 and, to date, vaccine manufacturers in 11 developing countries have received grants to acquire the capacity to produce inactivated or live attenuated influenza vaccine for their populations. In addition, a centralized 'hub' has been established to facilitate training in the new technologies for scientists and regulators in the countries. This supplement of Vaccine is devoted to showcasing the interim results of the WHO initiative and the impressive progress made by the developing country manufacturers.


Subject(s)
Influenza Vaccines/supply & distribution , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Pandemics/prevention & control , Technology Transfer , Technology, Pharmaceutical/organization & administration , Animals , Birds , Developing Countries , Health Services Accessibility , Humans , Influenza in Birds , Technology, Pharmaceutical/legislation & jurisprudence , World Health Organization
4.
Vaccine ; 28(42): 6811-20, 2010 Oct 04.
Article in English | MEDLINE | ID: mdl-20659520

ABSTRACT

On February 17-18, 2010, the World Health Organization (WHO) convened the 6th meeting on the "Evaluation of pandemic influenza vaccines in clinical trials" to review the progress made on new A (H1N1) 2009 vaccines and prototype H5N1 vaccines and their evaluation in clinical trials. A number of vaccine types were reviewed, including classical egg-derived and cell culture-derived inactivated vaccines, such as split virus or whole-virion vaccines, and live-attenuated vaccines (LAIV), as well as vaccines developed using new technologies. The amount of antigen needed, the effect of adjuvants and the number of doses required to induce adequate antibody responses in various populations, together with the issue of safety of the vaccines, were major topics of the meeting. The effectiveness of H1N1 vaccines and the need for standardization of vaccine potency tests were also discussed. Independent of the vaccine type and the presence or absence of an adjuvant, all A (H1N1) 2009 vaccines were well tolerated, eliciting only mild to moderate local or systemic reactions. For most vaccines tested, a single dose was sufficient to elicit a potentially protective antibody response in the majority of vaccinees >10 years of age. However, a second dose of vaccine was needed to boost immune responses in infants and toddlers 6 months to 3 years of age and, with some vaccines, in children aged 3-9 years.


Subject(s)
Influenza Vaccines/immunology , Influenza, Human/prevention & control , Antibodies, Viral/blood , Child , Child, Preschool , Congresses as Topic , Humans , Infant , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H5N1 Subtype , Influenza Vaccines/standards , Pandemics/prevention & control , Vaccines, Attenuated/immunology , Vaccines, Attenuated/standards , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , World Health Organization
5.
Vaccine ; 28(23): 3875-82, 2010 May 21.
Article in English | MEDLINE | ID: mdl-20398616

ABSTRACT

Current influenza vaccines are limited by the need for annual immunisation, frequent antigenic updating to match the evolution of circulating influenza virus strains, and reduced efficacy in elderly persons. On 9-10 November 2009, the Initiative for Vaccine Research of the World Health Organization convened jointly with the Wellcome Trust in London, United Kingdom, the fourth meeting on 'Influenza vaccines that induce broad spectrum and long-lasting immune responses'. Presentations were made by representatives from industry, academia, governmental and non-governmental organisations. The objectives of the meeting were to update the progress of research in the field of influenza vaccine strategies able to generate cross protection against divergent influenza virus strains. Improvements in existing strategies including live attenuated influenza vaccines and adjuvantation of inactivated vaccines were summarised. Developments in novel antigen production methods, new routes of vaccine delivery and administration, and vaccine approaches based on conserved virus antigens were explored. In addition, correlates of immune protection and regulatory issues for the evaluation and approval of future novel vaccine strategies were discussed.


Subject(s)
Influenza Vaccines/immunology , Influenza, Human/prevention & control , Adjuvants, Immunologic/pharmacology , Cross Protection , Disease Outbreaks/prevention & control , Humans , Influenza A virus/immunology , Influenza, Human/epidemiology , Vaccines, Attenuated/immunology , Vaccines, Inactivated/immunology , World Health Organization
7.
Vaccine ; 27(31): 4079-89, 2009 Jun 24.
Article in English | MEDLINE | ID: mdl-19406184

ABSTRACT

Influenza vaccines are potentially the most efficacious means of mitigating the impact of influenza pandemic and might contribute to the rapid containment of an emerging pandemic virus. On the 12-13 February 2009, the Initiative For Vaccine Research (IVR) of the World Health Organisation convened the 5th meeting on the 'Evaluation of pandemic influenza prototype vaccines in clinical trials' in Geneva. This was a follow-up meeting to the 4th meeting held on 14-15 February 2008 [Girard M, Palkonyay L, Kieny MP. Report of the 4th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials. Vaccine 2008;26:4975-7], and presentations were made by representatives from industry, academia, and governmental organisations. This year's meeting aimed to update the progress made during the past year on H5N1 and other prototype pandemic vaccines that have undergone clinical trials. A number of vaccine types were covered, including classical egg-derived inactivated vaccines, cell-derived inactivated vaccines, live-attenuated vaccines (LAIV) and vaccines developed using new technologies. The effects of different adjuvants and prime-boosting schedules were important topics, and further data were presented to show that children mount vigorous antibody responses to several H5N1 vaccines. Other subjects presented and discussed were standardisation, and regulatory issues concerning pandemic vaccines.


Subject(s)
Disease Outbreaks/prevention & control , Influenza Vaccines/immunology , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Adjuvants, Immunologic/pharmacology , Humans , Influenza A Virus, H5N1 Subtype/immunology , Switzerland , Vaccines, Attenuated/immunology , Vaccines, Inactivated/immunology , World Health Organization
10.
Clin Rheumatol ; 26(5): 753-8, 2007 May.
Article in English | MEDLINE | ID: mdl-17332982

ABSTRACT

Our objective was to investigate symptoms of depression in early rheumatoid arthritis (eRA) patients, and follow them longitudinally during a 3-year prospective study of 73 Hungarian and 45 Austrian early rheumatoid arthritis patients. Compared to validated national population data, mild symptoms of depression were detected in Hungarian early rheumatoid arthritis patients, which were independent of corticosteroid use. In the Hungarian subgroup, the Beck Depression Inventory scores were found to be stable during follow-up. Except at the baseline visit, depressive symptoms and functional status, as measured by the Health Assessment Questionnaire, were correlated. Significant differences were detected between Austrian and Hungarian patients despite of their geographical and cultural proximity. The mean depression score was higher in the Hungarian when compared to the Austrian patients. Depression is an important feature of early rheumatoid arthritis. Studies assessing depression in rheumatoid arthritis patients must be based on validated national data of normal population.


Subject(s)
Arthritis, Rheumatoid/psychology , Depression/diagnosis , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Depression/epidemiology , Depression/etiology , Female , Humans , Longitudinal Studies , Male , Middle Aged , Prevalence
11.
Hum Vaccin ; 1(4): 140-2, 2005.
Article in English | MEDLINE | ID: mdl-17012864

ABSTRACT

In response to concerns about interactions of academic and public health investigators with industry, the Canadian Association for Immunization Research and Evaluation (CAIRE), in collaboration with six major vaccine manufacturers, developed guidelines for participation in industry-sponsored clinical trial and epidemiology contract research within Canada. Topics addressed include definition of investigators, data ownership, protocol development, data management, data analysis, producing a study report and publication of the results of the study.


Subject(s)
Clinical Trials as Topic/standards , Drug Industry/standards , Immunization/standards , Research/standards , Canada , Clinical Protocols , Data Interpretation, Statistical , Humans , Publications , Terminology as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...